文献速递妇科

腹腔内顺铂和多柔比星治疗复发卵巢癌及腹膜癌的I期单臂开放标签剂量递增研究

A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis.
PubMed 文献 · Gynecol Oncol · 2018-05-06

本研究为I期单臂开放标签剂量递增试验,采用3+3设计,评估腹腔内加压气溶胶化疗(PIPAC)给予顺铂和多柔比星的剂量限制性毒性。15例可评估患者平均接受2.3个PIPAC周期,未发现剂量限制性毒性,未达到最大耐受剂量。组织学肿瘤消退在≥2周期患者中为7/11(64%)。作者认为顺铂10.5 mg/m2和多柔比星2.1 mg/m2的腹腔内剂量可安全使用,全身毒性低。

要点

  • PIPAC顺铂和多柔比星未达到最大耐受剂量,未发现剂量限制性毒性。
  • 仅1例3级不良事件(结肠穿孔),85例次1/2级事件,无肝肾功能及血液学毒性。
  • ≥2周期患者组织学肿瘤消退7/11(64%)。

核心结论

  • PIPAC顺铂和多柔比星可能以腹腔内剂量10.5 mg/m2和2.1 mg/m2安全使用,全身毒性低。

研究设计与样本

  • I期单臂非随机开放标签剂量递增试验,采用标准3+3设计,多柔比星1.5 mg/m2、顺铂7.5 mg/m2每4至6周一次共3周期,后续剂量递增步骤每步增加20%。
  • 15例可评估的复发卵巢癌和腹膜癌患者,队列1、2、3分别3、7、5例,平均接受2.3个PIPAC周期。

主要发现

  • 未发现剂量限制性毒性,未达到最大耐受剂量。
  • 不良事件包括1例3级事件(结肠穿孔)和85例次1/2级事件:疲劳(n=19)、腹痛(n=18)、恶心/呕吐(n=14)、睡眠障碍(n=8)、腹泻(n=5)、发热(n=2)。
  • 3个队列均未观察到肝毒性:AST分别为19.1±3.2、25.8±6.5、22.1±4.5 IU/L;ALT分别为14.7±3.5、18.5±5.6、23.3±13.0 IU/L;GGT分别为45.7±35.1、25.2±10.3、43.9±26.4 IU/L。
  • 3个队列均未观察到肾毒性:血清肌酐分别为1.06±0.23、0.80±0.17、0.89±0.35 mg/dL。
  • 未观察到全身血液学毒性、脱发或神经毒性;接受≥2个PIPAC周期的患者中7/11(64%)观察到组织学肿瘤消退。

临床怎么用

  • 作者认为PIPAC顺铂和多柔比星可能以腹腔内剂量10.5 mg/m2和2.1 mg/m2安全使用,全身毒性低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We performed a phase I, single-arm, non-randomized, open-label, dose-escalation trial to determine the dose-limiting toxicity of intraperitoneal cisplatin and doxorubicin applied as pressurized intraperitoneal aerosol chemotherapy (PIPAC) in women with recurrent ovarian cancer. METHODS: We used a standard 3 + 3 dose-escalation design with doxorubicin 1.5 mg/m2, cisplatin 7.5 mg/m2 q 4 to 6 weeks for 3 cycles and subsequent dose escalation steps (20% increment per step) in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Toxicity and clinical efficacy were monitored. The primary endpoint was the maximum-tolerable dose. Secondary endpoints included histologic tumor regression and serum parameters. RESULTS: 15 evaluable patients (3, 7, and 5 in cohorts 1, 2, and 3, respectively) on average received 2.3 PIPAC cycles. No dose limiting toxicities were found. Adverse side effects were 1 grade 3 event (colon perforation) and 85 grade 1/2 events including fatigue (n = 19), abdominal pain (n = 18), nausea/vomiting (n = 14), sleep disorder (n = 8), diarrhea (n = 5), and fever (n = 2). Liver and renal toxicity was not observed in any of the 3 cohorts (AST 19.1 ± 3.2, 25.8 ± 6.5, and 22.1 ± 4.5 IU/L, respectively; ALT 14.7 ± 3.5, 18.5 ± 5.6, and 23.3 ± 13.0 IU/L, respectively; GGT 45.7 ± 35.1, 25.2 ± 10.3, and 43.9 ± 26.4 IU/L, respectively; serum creatinine 1.06 ± 0.23, 0.80 ± 0.17, and 0.89 ± 0.35 mg/dL, respectively). No systemic hematologic toxicity, alopecia, or neurotoxicity was noted. The maximum tolerable dose was not reached. Histologic tumor regression was observed in 7/11 (64%) patients who underwent ≥2 PIPAC cycles. CONCLUSIONS: PIPAC with cisplatin and doxorubicin may be safely used at an intraperitoneal dose of 10.5 mg/m2 and 2.1 mg/m2, respectively. Systemic toxicity of this therapy is low.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Tempfer CB, Giger-Pabst U, Seebacher V, et al. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Gynecol Oncol. 2018. PMID: 29743140. doi:10.1016/j.ygyno.2018.05.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。